Exploring Sarcopenia in Parkinson's Disease Patients by Combining Serum Biomarker Levels

NCT06511531 | Not Yet Recruiting

• 1 other identifier: Xiangya_PD and Sarcopenia
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Parkinson\'s Disease (PD) and sarcopenia are prevalent age-related syndromes, often occurring simultaneously within individuals. Sarcopenia is notably common among PD patients, with severe cases affecting approximately one in every five individuals with PD. Moreover, sarcopenia is closely linked to the accelerated progression of PD, diminished quality of life, heightened mortality risk, and increased susceptibility to falls and fractures. Therefore, early detection of sarcopenia assumes particular significance as it offers an opportunity for interventions aimed at mitigating or delaying muscle degeneration, potentially influencing PD outcomes. This review will delve into the relationship between sarcopenia and PD, methods for screening and testing sarcopenia, and potential avenues for further research and the development of strategies for risk reduction and treatment

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• the SARC-F

  The SARC-F is a simple screening tool for sarcopenia, consisting of five questions on strength, assistance in walking, rising from a chair, climbing stairs, and falls. Each question is scored from 0 to 2, with a total score of 4 or more indicating a risk of sarcopenia.

  12 months

Secondary Outcomes (3)

• Low Muscle Mass

  12 months

• Low Muscle Strength

  12 months

• Poor Physical Performance

  12 months

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Age ≥ 30 years

You may qualify if:

• Diagnosed as either ''definite'' or ''probable'' PD based on Chinese diagnostic criteria of Parkinson\'s disease (2016 version)

You may not qualify if:

• Parkinson\'s syndrome or Parkinsonian superimposed syndrome due to encephalitis, cerebrovascular disease, poisoning, trauma, drugs or other factors

Sponsors & Collaborators

• Central South University: lead

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Qin Lixia, Principal Investigator

CONTACT

+86 18207406524; qinlixia1027@csu.edu.cn

Gui Meilin, student

CONTACT

+86 15286516701; guimeilin2021@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 22, 2024
• First Posted: July 22, 2024
• Study Start: August 1, 2024
• Primary Completion: August 1, 2024
• Study Completion: September 1, 2024
• Last Updated: July 22, 2024

Record last verified: 2024-07